Search

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

Congress platform

The EHA2024 Hybrid Congress content is entirely accessible on the Congress platform.  

Access the EHA2024 Congress platform 

To access the Congress platform, please use your credentials.

Read more

Chairs and Members

ChairProf Dr Carlo Dufour, Gaslini Children’s Research Hospital, Genova (Italy)

Co-chairProf Dr Helen Papadaki, Institution University Hospital of Heraklion, Heraklion, Crete (Greece)

SWG Executive Board members
Kim De Keersmaecker, University of Leuven (Belgium)
Francesca Fioredda, G.

Read more

EHA Congratulates EHA Kick-Off Grant 2022 Winners

The Hague, December 8, 2022 – EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2022 after a rigorous selection process.

Read more

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more